- Home
- ACON
ACON
Aclarion Inc.
as of 01-30-2026 3:10pm EST
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | BROOMFIELD |
| Market Cap: | 4.4M | IPO Year: | 2022 |
| Target Price: | $23.00 | AVG Volume (30 days): | 2.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -12.69 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.55 - $562.68 | Next Earning Date: | 11-12-2025 |
| Revenue: | $67,483 | Revenue Growth: | 36.91% |
| Revenue Growth (this year): | 71.77% | Revenue Growth (next year): | 80.52% |
AI-Powered ACON Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Compare ACON vs Leading Stocks
See how ACON stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ACON Aclarion Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.